The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Epiregulin (EREG) and amphiregulin (AREG) gene expression to predict response to cetuximab therapy in combination with oxaliplatin (Ox) and 5FU in first-line treatment of advanced colorectal cancer (aCRC).
Richard A. Adams
Honoraria - Merck Serono
Research Funding - Merck Serono
David Fisher
No relevant relationships to disclose
Susan Farragher
Employment or Leadership Position - Almac Diagnostics
Alastair Scott
Employment or Leadership Position - Almac Diagnostics
Christopher G Smith
No relevant relationships to disclose
Michelle D James
No relevant relationships to disclose
Jeremy Cheadle
No relevant relationships to disclose
Laura L Nichols
No relevant relationships to disclose
Angela M. Meade
No relevant relationships to disclose
Richard S. Kaplan
No relevant relationships to disclose
Richard H. Wilson
No relevant relationships to disclose
Harpreet S Wasan
Honoraria - Merck KGaA; Merck Serono; Sanofi
Tim Maughan
No relevant relationships to disclose